IBM Micromedex: Comprehensive evidence built upon robust editorial review methodologies

Comprehensive clinical content for heightened confidence

Our robust editorial processes support the comprehensive clinical evidence in IBM® Micromedex®

Patient safety is a priority, and healthcare professionals look for clinically-relevant robust evidence to support critical decisions. Our in-house editorial staff undergo meticulous training, and the process used to develop the content in Micromedex has received accreditation from NICE. Because our clinicians complete extensive evaluation and synthesis of the literature and assess information across multiple content areas, customers using Micromedex can be confident that our clinical content is designed to contain clinically accurate, relevant and consistent information.

We review world medical literature

- Approximately 15,000 medical articles published each week
- Approximately 8,500 journals monitored
- Both high level and in-depth reviews performed regularly

In-house editorial team

Clinically-trained editorial staff with expertise in research methodology
Surveillance
Ongoing surveillance of worldwide biomedical literature and regulatory actions.

Evaluation
Identification of methodologically solid literature on a topic from a variety of sources, and determination of clinical significance.

Content creation
Our specialists work across drug, disease, toxicology and patient education for consistency across all content sets.

Internal and external review
Content reviewed for clinical accuracy and relevance. Additional review by editorial board members for critical content areas.

Fortified evidence
Objectively validated by academics and professionals.

Final review and publish

Our procedures include:
- Multi-step editorial process and documented policies
- Ongoing surveillance and critical evaluation of primary literature
- In-house editorial team of clinically-trained editorial staff
- Single editorial group and process ensures consistent content
- In-line referencing and supporting studies provides transparency
- Consistent coverage of off-label and therapeutic uses
- Inclusion of strength of efficacy and evidence ratings to aid clinicians in their treatment decisions

Get connected
email: micromedex@us.ibm.com

About IBM Watson Health
Each day, professionals throughout the health ecosystem make powerful progress toward a healthier future. At IBM Watson Health, we help them remove obstacles, optimize efforts and reveal new insights to support the people they serve. Working across the landscape, from payers and providers to governments and life sciences, we bring together deep health expertise; proven innovation; and the power of artificial intelligence to enable our customers to uncover, connect and act — as they work to solve health challenges for people everywhere.

For more information on IBM Watson Health, visit: ibm.com/watsonhealth

The National Institute for Health and Care Excellence (NICE) has accredited the process used by Truven Health Analytics to develop content used in its Micromedex solutions.¹
Foonotes

© Copyright IBM Corporation 2018
IBM Corporation
Route 100
Somers, NY 10589
Produced in the United States of America
April 2018
IBM, the IBM logo and ibm.com and IBM Watson Health are trademarks of IBM Corporation in the United States, other countries or both. Truven Health Analytics and its respective logo are trademarks of Truven Health Analytics in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies. A current list of IBM trademarks is available on the Web at “Copyright and trademark information” at www.ibm.com/legal/copytrade.shtml.

This document is current as of the initial date of publication and may be changed by IBM at any time. Not all offerings are available in every country in which IBM operates.

The information in this document is provided “as is” without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. IBM products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it.

IBM does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation.

The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user’s responsibility to evaluate and verify the operation of any other products or programs with IBM product and programs.

Statement of Good Security Practices:
IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. IBM systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. IBM does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.

Notes